|
Market Closed -
Other stock markets
|
Pre-market 18:14:33 | |||
| 211.04 USD | -3.19% |
|
209.92 | -0.53% |
| 07-31 | Mizuho Trims Price Target on Axsome Therapeutics to $306 From $310, Keeps Outperform Rating | MT |
| 07-21 | BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- AXSM Stock
- Consensus Axsome Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
